Product Lifecycle Management (LCM)

Developing Solid Oral Dosage Forms

Volumn , Issue , 2009, Pages 911-921

  Zannou, Erika A ^a   Li, Ping ^a   Tong, Wei Qin ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Teva Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882859127     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-444-53242-8.00040-0     Document Type: Chapter

References (23)

1. Rhodes, J. & Mulder, J. (2005). Challenges and opportunities converge in today's pharmaceutical industry. http://www.deloitte.com/us/lifesciences.
2. Capgemini. (2004). Pharmaceutical industry success dependent on better product lifecycle management. , October 6. http://www.capgemini.com.
3. Visiongain. (2006). Product lifecycle management. Strategic report, , May. http://www.piribo.com.
4. Slowik, H. (2003). The battle for IP. In Vivo: The Business and Medicine Report 21(6), 75-82.
5. Lucas J., Burgess P. When form equals substance: The value of screening in product life-cycle management. Pharma Voice 2004, February.
6. Tong, W.Q. (2004). Integrating business considerations into scientific approaches for salt and crystal form screening and selection, 43rd annual Eastern Pharmaceutical Technology Meeting, October 1.
7. McGinity J.W., Zhang F., Repka M.A., Koleng J.J. Hot-melt extrusion as a pharmaceutical process 2001, American Pharmaceutical Review, Russell Publishing.
8. Douglas S.J., Davis S.S., Illum L. Nanoparticles in drug delivery. CRC Critical Review Ther. Drug Carr. Syst. 1987, 3(3):233-261.
9. Rajabi-Siahboomi A.R., Melia C.D., Davies M.C., Bowtell R.W., McJury M., Sharp J.C., Mansfield P. Imaging the internal structure of the gel layer in hydrophilic matrix systems by NMR imaging. J. Pharm. Pharmacol. 1992, 44(suppl):1062.
10. Liversidge, G.G., Cundy, K.C., Bishop, J. & Czekai, D. (1991). Surface modified drug nanoparticles. US Patent 5145 684.
11. Charman W.N. Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J. Pharm. Sci. 2000, 89:967-978.
12. Holt D.W., et al. Trans. Proc. 1994, 26(5):2935-2939.
13. Bangalore S., Kamalakkannan G., Parkar S. Fixed-dose combinations improve medication compliance: A meta-analysis. The American Journal of Medicine 2007, 120:713-719.
14. Wald N.J., Law M.R. A strategy to decrease cardiovascular disease by more than 80%. BMJ 2003, 326(7404):1419.
15. Workshop on Challenges in developing fixed-dosed combination oral solid dose products, 13-14 September. Pharmaceutical Research 2006, 23(9):2230-2231. AAPS (American Association of Pharmaceutical Scientists), Arlington, VA.
16. Beers D.O. An increase in life expectancy 2002, Legal Week Global November, Arnold & Porter LLP.
17. European Medicines Agency (EMEA). (2008). Committee for Medical Products for Human Use (CHMP), Draft Guideline on fixed combination medicinal products, 21 February, . http://www.emea.europa.eu/pdfs/human/ewp/024095en.pdf.
18. Food and Drug Administration (FDA). (2006). US Department of Health and Human Services, Guidance for Industry and FDA Staff, Early Development Considerations for Innovative Combination Products, September, . http://www.emea.europa.eu/pdfs/human/ewp/024095en.pdf.
19. Lehman Brothers. (2007). Pharma Pipelines. Strategic Analysis and Conclusions 2007, September 19, . http://www.lehman.com.
20. Lifecycle Management Strategies. (2006). Maximizing ROI through indication expansion, reformulation and Rx-to-OTC switching, Business Insights Limited, February, . http://www.bioportfolio.com/cgi-bin/acatalog/info_333.html.
21. Pharmaceutical Law & Industry Report. (2003). Vol. 1, No.11, March 28, pp. 312-316.
22. Rathbone, M. J., Hadgraft, J. & Roberts, M. S. (2003). Modified release drug delivery technologies. Drugs and Pharmaceutical Sciences, Vol. 126. Informa Health Care.
23. United States Code of Federal Regulations (21 CFR).